论文部分内容阅读
基于抗独特型抗体在免疫网络中的特殊地位,尤其是抗独特型抗体在肿瘤免疫治疗及预防中的潜力引起了广泛兴趣,国外已对多种实体瘤制备了相应抗独特型抗体,并已(或准备)试用于临床。但未见有鼻咽癌抗独特型抗体的研究报导。鼻咽癌为我国有区域性分布的高发肿瘤,对其常规治疗之外的免疫治疗研究不够充分,因此我们制备出鼻咽癌抗独特型抗体并进行特异主动免疫治疗研究。用鼻咽癌细胞株CNE-1作抗原,制备出一株抗人鼻咽癌杂交瘤细胞系Fc1,Fc1单克隆抗体对靶细胞有良好的亲和力,特异性也较好,作用部位为癌细胞膜上的肿瘤相关抗原。用Fc1(Ab1)作免疫原,制备出一株抗Fc1V区独特型的杂交瘤2A9。2
Based on the particular status of anti-idiotypic antibodies in immune networks, and especially the potential of anti-idiotypic antibodies in tumor immunotherapy and prevention, widespread interest has been attracted. Corresponding anti-idiotypic antibodies have been prepared in various solid tumors in foreign countries. (Or prepared) trial for clinical use. But no nasopharyngeal carcinoma anti-idiotypic antibodies reported. Nasopharyngeal carcinoma is a highly localized tumor in our country, and its immune therapy is not sufficient for its routine treatment. Therefore, we prepared anti-idiotypic antibodies of nasopharyngeal carcinoma and carried out specific active immunotherapy. Using nasopharyngeal carcinoma cell line CNE-1 as an antigen, an anti-human nasopharyngeal carcinoma hybridoma cell line Fc1 was prepared. The monoclonal antibody against Fc1 had good affinity and specificity for target cells and the site of action was cancer cell membrane On the tumor-associated antigen. Using Fc1 (Ab1) as an immunogen, a hybridoma 2A9.2